Market Overview

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Share:
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Last week could be termed as a mixed one for the biotech sectors. Big pharma earnings came in mostly positive, but the FDA rejected two NDAs, pressuring Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) and Heron Therapeutics Inc (NASDAQ: HR).

The following are key catalysts for the unfolding week.

Conferences

  • 16th International Conference on Breast Pathology and Cancer Diagnosis: May 10-11 in Montreal, Canada. 
  • 2019 American Academy of Neurology annual meeting: May 4-10 in Philadelphia, Pennsylvania.
  • American Urological Association 2019 annual meeting: May 3-6 in Chicago, Illinois.
  • Hemostasis & Thrombosis Society 2019 Scientific Symposium: May 9-11 in New Orleans, Louisiana.

Clinical Trial Readouts

American Academy of Neurology Annual Meeting Presentations

Novartis AG (NYSE: NVS): Data from the Phase 3 SPRINT study for Zolgensma (pre-symptomatic patients with spinal muscular atrophy Types 1, 2 and 3 — as well Phase 1 data for Zolgensma in SMA Type 2 — on May 5.

Cytokinetics, Inc. (NASDAQ: CYTK): Phase 2 data for Reldesemtiv in a study dubbed FORTITUDE-ALS (amyotrophic lateral sclerosis) on May 5.

MediciNova, Inc. (NASDAQ: MNOV): additional Phase 2b data for MN-166 (progressive multiple sclerosis) on May 6.

PTC Therapeutics, Inc. (NASDAQ: PTCT) and Roche Holdings AG Basel ADR (OTC: RHHBY): Phase 2/3 data for RG7916 from a study dubbed SUNFISH (spinal muscular dystrophy) on May 7.

Ra Pharmaceuticals Inc (NASDAQ: RARX): already released Phase 2 data for RA101495, or zilucoplan, (myasthenia gravis) on May 7.

PTC Therapeutics: Phase 2/3 data for RG7916 from a study dubbed Firefish (spinal muscular dystrophy) on May 7.

See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

American Urological Association 2019 Annual Meeting Presentations

Urovant Sciences Ltd (NASDAQ: UROV): already released Phase 3 data for Vibegron (overactive bladder) on May 5.

Urogen Pharma Ltd (NASDAQ: URGN): already released Phase 3 data for MitoGel (urothelial carcinoma) on May 5.

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX): Phase 2/3 data for PyL (prostate cancer) on May 6.

Earnings Highlights

Monday, May 6

  • GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) (after the market close)
  • Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (after the market close)

Tuesday, May 7

  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the market open)
  • Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the market close)

Wednesday, May 8

  • Portola Pharmaceuticals Inc (NASDAQ: PTLA) (before the market open)
  • Dynavax Technologies Corporation (NASDAQ: DVAX) (after the market close)

Thursday, May 9

  • Ionis Pharmaceuticals Inc (NASDAQ: IONS) (before the market open)
  • Puma Biotechnology Inc (NASDAQ: PBYI) (after the market close)

IPOs

Applied Therapeutics, a biotech company developing therapies for diabetic cardiomyopathy, is due to offer 4 million shares in an IPO that are likely to be priced between $14 and $16. The shares are to be listed on the Nasdaq under the ticker symbol APLT.

Axcella proposes to offer 3.57 million shares in an IPO with an estimated price range of $20-$22. The biotech developing therapies and food to treat metabolic dysregulation in the liver seeks to list its shares on the Nasdaq under the ticker symbol AXLA.

Cortexyme, which develops a novel therapy for Alzheimer's disease, is expected to offer 4.412 million shares with an estimated price range of $16-$18. The company is to list its shares on the Nasdaq under the ticker symbol CRTX.

Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, plans to offer 5 million shares to be priced between $14 and $16. The shares are to be listed on the Nasdaq under the ticker symbol MIST.

NextCure is scheduled to offer 5 million shares in an IPO, to be priced in the range of $14-$16. The shares of the cancer immunotherapy company are due to be listed on the Nasdaq under the ticker symbol NXTC.

 

Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Previews IPOs Top Stories Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com